The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Treating DLBCL with CAR-T: the best candidates and selecting a CAR-T product
Charalambos Andreadis, MD, MSCE, UCSF Health, San Francisco, CA, briefly comments on the best time to use CAR T-cell therapy in patients with diffuse large B-cell lymphoma (DLBCL). Phase III data suggest that CAR-T is very effective in treating patients who experience early progression or relapse, and this therapeutic approach has a more significant clinical benefit than autologous stem cell transplantation (autoSCT) in many patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Kite/Gilead, BMS, Novartis; Grants or contracts: BMS, Novartis, Genentech; Research Funding: Merck & Co., Inc.
